Thyroid Autoantibodies and Treatment Response in Chronic Spontaneous Urticaria

A retrospective cohort study of 350 euthyroid chronic spontaneous urticaria patients from 2020 to 2023, analyzing associations between thyroid autoantibodies and treatment outcomes. The dataset includes primary endpoints like Week 24 treatment response and secondary outcomes such as time-to-response and relapse rates. It was created by Lizhen Zhuang to investigate the prognostic value of TPOAb/TgAb positivity.

Use Cases

• Model the association between thyroid autoantibody (TPOAb/TgAb) status and Week 24 treatment response using conditional logistic regression.
• Analyze time-to-response data with Cox proportional hazards models to assess delays in antibody-positive patients.
• Compare relapse rates and treatment escalation requirements (e.g., omalizumab, cyclosporine use) across antibody status subgroups.
• Investigate the dose–response gradient in patients who are dual-positive for autoantibodies versus single-positive or negative patients.

Strengths

• Contains data from 350 patients, a substantial cohort for a clinical study.
• Includes multiple clinical endpoints: Week 24 response, time-to-response, relapse rates, and specific treatment escalation data.
• Data is from a recent time period (2020-2023) and was last updated in 2026.

Limitations

• The dataset is small in file size (304.9 KB), suggesting limited raw data or a summary document rather than a full tabular dataset.
• Specific column definitions, row counts, and sample data are unavailable, limiting direct analytical use.
• As a retrospective study, it may have inherent biases not fully adjusted for by propensity score matching.

Provenance

Source

figshare, authored by Lizhen Zhuang.

Collection Method

Propensity score-matched retrospective cohort study.

Time Range

2020 to 2023.

Freshness

Data covers 2020-2023; metadata was last updated on 2026-03-23.